AI Clinical Validation In Drug Discovery

AI clinical validation in drug discovery is the source’s check on AI drug enthusiasm in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. [[XiaoPTeacher|小P老师]] treats AI as a 2025 watch direction for molecular design, large-molecule sequence optimization, and target selection, but says prior AI-drug clinical disclosures cooled the market when data looked weak.

This concept complements AI Drug Discovery Platform. The platform page focuses on model and business design; this page names the clinical burden: a generated molecule or target hypothesis only matters if it survives wet-lab, translational, safety, and human outcome tests.

Key Claims

• AI can help with molecular design, protein or large-molecule sequence optimization, and earlier target selection.
• Platform narratives are insufficient without clinical evidence.
• Weak clinical data can quickly reprice AI-drug enthusiasm even if the model story remains attractive.
• AI Verification is harder in drug discovery because verification may require long, expensive biological and clinical loops.

Connections

• AI Drug Discovery Platform, AI For Science, and AI Protein Design - adjacent AI-for-biology concepts.
• AI Verification, Domain Expert Alignment, and Research Taste - validation and problem-selection constraints.
• Platform-Pipeline Biotech Strategy - business model question around proving value through owned pipelines.
• 小P老师 / Xiao P Teacher - source viewpoint.